Journal
Clinical & Translational Immunology
Publication Date
1-1-2023
Volume
12
Issue
6
First Page
e1455
Document Type
Open Access Publication
DOI
10.1002/cti2.1455
Rights and Permissions
Docherty, C.A., Fernando, A.J., Rosli, S., Lam, M., Dolle, R.E., Navia, M.A., Farquhar, R., La France, D., Tate, M.D., Murphy, C.K., Rossi, A.G. and Mansell, A. (2023), A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases. Clin Transl Immunol, 12: e1455. https://doi.org/10.1002/cti2.1455 © 2023 Adiso Therapeutics and The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Recommended Citation
Docherty, Callum Ah; Fernando, Anuruddika J; Rosli, Sarah; Lam, Maggie; Dolle, Roland E; Navia, Manuel A; Farquhar, Ronald; La France, Danny; Tate, Michelle D; Murphy, Christopher K; Rossi, Adriano G; and Mansell, Ashley, "A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases." Clinical & Translational Immunology. 12, 6. e1455 (2023).
https://digitalcommons.wustl.edu/oa_4/2929
Additional Links
Supplemental material is available for this article at publisher site.
